197 related articles for article (PubMed ID: 31289206)
1. Human BCR/ABL1 induces chronic myeloid leukemia-like disease in zebrafish.
Xu M; Ye Y; Ye Z; Xu S; Liu W; Xu J; Zhang Y; Liu Q; Huang Z; Zhang W
Haematologica; 2020 Mar; 105(3):674-686. PubMed ID: 31289206
[TBL] [Abstract][Full Text] [Related]
2. Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms.
Zizioli D; Bernardi S; Varinelli M; Farina M; Mignani L; Bosio K; Finazzi D; Monti E; Polverelli N; Malagola M; Borsani E; Borsani G; Russo D
Cells; 2021 Feb; 10(2):. PubMed ID: 33669758
[TBL] [Abstract][Full Text] [Related]
3. c-myb is involved in CML progression and is a therapeutic target in the zebrafish CML model.
Ye Y; Yang X; Li F; Liu W; Zhang W; Huang Z
Animal Model Exp Med; 2024 Apr; 7(2):136-144. PubMed ID: 36300552
[TBL] [Abstract][Full Text] [Related]
4. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML.
Honda H; Ushijima T; Wakazono K; Oda H; Tanaka Y; Aizawa Si; Ishikawa T; Yazaki Y; Hirai H
Blood; 2000 Feb; 95(4):1144-50. PubMed ID: 10666183
[TBL] [Abstract][Full Text] [Related]
5. Examination of clinically-derived p210 BCR/ABL1 RhoGEF mutations in a murine bone marrow transplantation model of CML.
Ciccarelli BT; Hu T; Wang Q; Kim JJ; Whitehead IP
Leuk Res; 2020 Oct; 97():106440. PubMed ID: 32892149
[TBL] [Abstract][Full Text] [Related]
6. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
Pear WS; Miller JP; Xu L; Pui JC; Soffer B; Quackenbush RC; Pendergast AM; Bronson R; Aster JC; Scott ML; Baltimore D
Blood; 1998 Nov; 92(10):3780-92. PubMed ID: 9808572
[TBL] [Abstract][Full Text] [Related]
7. Erythroid variant evolving from chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitors: a rare case report.
Lee MH; Song A; Li JY
Diagn Pathol; 2024 Jan; 19(1):21. PubMed ID: 38268039
[TBL] [Abstract][Full Text] [Related]
8. Validation of a
Outa AA; Abubaker D; Bazarbachi A; Sabban ME; Shirinian M; Nasr R
Haematologica; 2020; 105(2):387-397. PubMed ID: 31101753
[TBL] [Abstract][Full Text] [Related]
9. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
10. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
[TBL] [Abstract][Full Text] [Related]
11. p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.
van Rhee F; Hochhaus A; Lin F; Melo JV; Goldman JM; Cross NC
Blood; 1996 Jun; 87(12):5213-7. PubMed ID: 8652835
[TBL] [Abstract][Full Text] [Related]
12. BCR-ABL1 p210 screening for chronic myeloid leukemia in patients with peripheral blood cytoses.
Fenu E; O'Neill SS; Insuasti-Beltran G
Int J Lab Hematol; 2021 Dec; 43(6):1458-1464. PubMed ID: 34185393
[TBL] [Abstract][Full Text] [Related]
13. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
[TBL] [Abstract][Full Text] [Related]
14. Genomic mechanisms of p210BCR-ABL signaling: induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis.
Ray S; Lu Y; Kaufmann SH; Gustafson WC; Karp JE; Boldogh I; Fields AP; Brasier AR
J Biol Chem; 2004 Aug; 279(34):35604-15. PubMed ID: 15155749
[TBL] [Abstract][Full Text] [Related]
15. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.
Koschmieder S; Göttgens B; Zhang P; Iwasaki-Arai J; Akashi K; Kutok JL; Dayaram T; Geary K; Green AR; Tenen DG; Huettner CS
Blood; 2005 Jan; 105(1):324-34. PubMed ID: 15331442
[TBL] [Abstract][Full Text] [Related]
16. Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with
Boucher L; Sorel N; Desterke C; Chollet M; Rozalska L; Gallego Hernanz MP; Cayssials E; Raimbault A; Bennaceur-Griscelli A; Turhan AG; Chomel JC
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895120
[TBL] [Abstract][Full Text] [Related]
17. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
Gross AW; Ren R
Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
[TBL] [Abstract][Full Text] [Related]
18. Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia.
Shin JE; Kim SH; Kong M; Kim HR; Yoon S; Kee KM; Kim JA; Kim DH; Park SY; Park JH; Kim H; No KT; Lee HW; Gee HY; Hong S; Guan KL; Roe JS; Lee H; Kim DW; Park HW
Mol Cancer; 2023 Nov; 22(1):177. PubMed ID: 37932786
[TBL] [Abstract][Full Text] [Related]
19. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S
Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601
[No Abstract] [Full Text] [Related]
20. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
